China-based pharmaceutical companies betting big and small biopharma able to quickly innovate will drive the use of AI for drug discovery – a market some analysts predict will reach a valuation of $20bn by 2024.
GE Healthcare’s Edison platform collaborates with ACR AI-Lab to extend its AI capabilities and allows ACR members access to algorithm creation in an aim to turn research into product development.
Deep Lens closes $14m Series A financing as it continues to expand its digital pathology platform to enable patient identification at time of diagnosis, fast-tracking trial enrollment.
Clinical AI, no matter how sophisticated, cannot work on its own, says Life Image CEO, who predicts that CROs will either adapt or be disrupted by smaller companies with digital access capabilities.
The oncology-focused alliance brings together Worldwide’s cancer research and clinical trial operations with Deep Lens’ Viper digital pathology platform.
Datathon participants identify five repurposable drug candidates, applying AI to identify genes of interest and support target identification – a task that previously would have taken years, says industry expert.
Artificial intelligence works best in a standardized environment, say industry experts. Workflows and processes must first be aligned to successfully use the technology – is pharma ready?
PPD’s agreement with China-based Happy Life Tech focuses on site selection, patient recruitment, and real-world evidence generation for customers globally.
Artificial intelligence advances threaten data privacy, according to a new study, which found it is possible to re-identify individuals using their physical activity data.
Though larger pharma companies are investing heavily in biologics, the industry is set to be predominantly focused on small molecules moving forwards, claims CAS MD.
Clinithink has secured investors to scale its technology, which leverages unstructured data to guide treatment decisions, identify clinical trial participants, and ensure proper reimbursement.
The biopharma industry is on the precipice of making personalized medicine a reality with access to massive amounts of data, computing power, and artificial intelligence to run in silico clinical trials, says GNS Healthcare CEO.
Merck’s agreement with Cyclica will establish efficiency in its small molecule therapy development with access to Cyclica’s AI protein screening platform.
While several companies touted the potential of AI to disrupt the drug development industry in 2018, what practical applications can the industry expect next year?
The information analytics business Elsevier has launched a new cloud-based data platform, Entellect, to de-silo, contextualize, and connect drug, target, and disease data.
Evotec and Immuneering are combining iPSC and AI technologies through a research collaboration to discover novel small molecules for rare hereditary metabolic diseases.
